The CD200R1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HAP1 cells with targeted disruption of the CD200R1 gene. This knockout product provides a genetically heterogeneous pool of loss-of-function cells for studying the CD200?CCD200R1 immune checkpoint. By eliminating CD200R1 expression, these cells enable investigation of inhibitory immune receptor signaling and support applications in drug discovery and target validation.
The HAP1 cell line is a near-haploid, fibroblast-like human cell line derived from a male chronic myeloid leukemia patient. It grows adherently and expresses the BCR-ABL fusion, but its near-haploid karyotype is key: it allows efficient CRISPR/Cas9-mediated gene disruption, as a single targeting event can abolish gene function. This genetic simplicity makes HAP1 an ideal host for functional genomics and knockout screening.
CD200R1 is an inhibitory immune receptor that negatively regulates myeloid and T cell activation. Ligand CD200 binding induces recruitment of SHP-1 and SHP-2 phosphatases via ITIM motifs, leading to dephosphorylation of signaling intermediates and suppression of MAPK and NF-??B pathways. This attenuates pro-inflammatory cytokine production (e.g., TNF-??, IL-6) and involves interacting factors DOK2 and RasGAP, positioning CD200R1 as a critical checkpoint in immune homeostasis.
In the HAP1 background, CD200R1 knockout provides a simplified model to dissect its signaling network independent of complex immune cell contexts. Although non-hematopoietic, HAP1 cells express pathway components and allow detailed analysis of how loss of CD200R1-mediated inhibition impacts MAPK/NF-??B activity. This model is useful for exploring the receptor’s role in cancer immune evasion, autoimmunity, and neuroinflammation, including Alzheimer??s disease pathology.
These polyclonal knockout cells are suitable for functional genomics screens, immune checkpoint studies, and drug target validation. Representative assays include flow cytometry for knockout confirmation, co-culture with CD200-expressing cells coupled with cytokine ELISA, and phospho-signaling analyses to measure MAPK/NF-??B activation. Cell viability assays further support functional readouts. For researchers seeking a robust tool to advance CD200R1 research, this product offers a versatile platform. For additional details, contact Ascent Research.
